{"nctId":"NCT01628965","briefTitle":"A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients","startDateStruct":{"date":"2008-01"},"conditions":["Parkinson's Disease"],"count":143,"armGroups":[{"label":"SPM 962","type":"EXPERIMENTAL","interventionNames":["Drug: SPM 962"]}],"interventions":[{"name":"SPM 962","otherNames":["rotigotine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject completed the preceding trial 243-07-001 (NCT00537485)\n\nExclusion Criteria:\n\n* Subject discontinued from the preceding trial 243-07-001.\n* Subject had a serious adverse event which association with the investigational drug was not ruled out during trial 243-07-001.\n* Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-07-001.\n* Subject had persistent hallucination or delusion during trial 243-07-001.\n* Subject has psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline.\n* Subject has orthostatic hypotension or a systolic blood pressure (SBP) \\<= 100 mmHg and has a decrease of SBP from spine to standing position \\>= 30 mmHg at baseline.\n* Subject has a history of epilepsy, convulsion etc. during trial 243-07-001.\n* Subject develops serious ECG abnormality at the baseline.\n* Subject has QTc-interval \\>= 500 msec at the baseline or subject has an increase of QTc-interval \\>= 60 msec from the baseline in the trial 243-07-001 and has a QTc-interval \\> 470 msec in female or \\> 450 msec in male at the baseline.\n* Subject has a serum potassium level \\< 3.5 mEq/L at the end of the taper period in trial 243-07-001.\n* Subject has a total bilirubin \\>= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or \\>= 100 IU/L) at the end of the period in trial 243-07-001.\n* Subject has BUN \\>= 30 mg/dL or serum creatinine \\>= 2.0 mg/dl at the end of the taper period in trial 243-07-001.\n* Subject who plans pregnancy during the trial.\n* Subject has dementia.\n* Subject is unable to give consent.\n* Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters","description":"Incidence and severity of adverse events, vital signs, and laboratory parameters up to 54 weeks after dosing.\n\n\\*decrease in difference between supine and standing systolic blood pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score","description":"Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum up to 54 weeks after dosingUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":"8.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"9.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"10.1"}]}]}]},{"type":"PRIMARY","title":"Skin Irritation Score of the Application Site","description":"Skin irritation score of the application site were evaluated according to the criteria below. The worst score throughout the treatment period was used in the analysis.\n\n-: no reaction, Â±: mild erythema, +: erythema, ++: erythema and Oedema, +++: erythema and oedema and rash papular, or serous papule, or vesicles, ++++: bullosum","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":143},"commonTop":["Application Site Reaction","Nausea","Nasopharyngitis","Vomiting","Constipation"]}}}